Palivizumab (synagis): counting "costs" and values.
Carter
B S
BS
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use*; D002648:Child; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D000069455:Palivizumab; D010372:Pediatrics / Q000191:economics; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000191:economics / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D022261:Respiratory Syncytial Virus Vaccines; D000069455:Palivizumab